Proliferation and generation of tumour cytotoxic lymphocytes in autologous mixed lymphocyte tumour cell culture (MLTC) can be obtained in a high percentage of tumour patients Vose & Bonnard, 1982) . In melanoma patients, however, the activation of lymphocytes by autologous melanoma cells (auto-Me) correlates with the patients' clinical stage, since primary but not metastatic melanoma cells are able to stimulate autologous peripheral blood lymphocytes (auto-PBL) Guerry et al., 1984) . Nevertheless, PBL from patients with primary or metastatic melanoma as well as from patients with tumours of different histologic origin can lyse autologous tumour cells after in vitro activation with a pool of allogeneic normal PBL (Zarling et al., 1978b; Strausser et al., 1981; Fossati et al., 1982; Mazumder et al., 1983) . The pathway of the allostimulation-induced killing of autologous tumour cells is still unclear since different types of effectors can be generated and expanded in mixed lymphocyte culture (MLC), including non-specific effectors such as NK-like cells or lymphokine-activated killer cells (LAK) (Grimm et al., 1982; Lopez-Bonet et al., 1982; MacPhail et al., 1984) . The cytotoxicity of alloactivated patients' PBL (Pt-PBL) might be specific and due either to a cross-reactivity between alloantigens and tumour cells (Zarling et al., 1978a; Parmiani et al., 1979) , or to the presence of T cells previously sensitized in vivo to tumour-associated antigens (TAA), and which are then activated and expanded during the MLC through the release of lymphokines, mainly interleukin 2 (IL-2) (Vose & White, 1983) . On the other hand, tumour cell lysis could be due to activation by IL-2 of NK-like cells which can lyse autologous and allogeneic tumour cells, or of LAK cells which can kill also NKresistant fresh tumours (Grimm et al., 1982; Lotze et al., 1981) .
The present study was undertaken to investigate the pathway of the MLC-generated auto-Me-cytotoxic PBL. We found that the lysis of auto-Me by allostimulated Pt-PBL was not due to a crossreaction between TAA and alloantigens, and that allostimulation leads to the generation of at least two different types of effectors, the first of which lyses auto-Me but not K562 targets and the second which recognizes NK-sensitive structures both on auto-Me and K562. The precursor cells of these two types of effectors are T3 + and T3 -respectively.
Materials and methods
Peripheral blood tymphocytes ( Tumour target cells The preparation of tumour cells has been described in detail elsewhere (Fossati et al., 1982) . Briefly, fresh tumour cells were obtained from lymph node metastases of malignant melanoma patients. When present, red blood cells were lysed by a 10min treatment with ammonium chloride at 4°C and dead cells were removed by treating the cell suspension with 0.25% of trypsin and DNase (240 U ml-1) at room temperature for 1 min. Tumour cells were frozen and stored in liquid nitrogen. These cells were thawed when needed and used as targets; in 20% of cases cultured melanoma cells were used as targets within the first 3-4 in vitro transfer generations. Both fresh cryopreserved and cultured target cells were of .80% viability when used as assessed by trypan blue exclusion, and had <5% obvious contamination with nonmalignant cells. K562, the NK-sensitive myeloid leukemia line, was cultured in CM and passaged weekly. Serological tests with monoclonal antibodies showed that our K562 line lacks MHC antigens.
In vitro activation systems Non-adherent (NA)-PBL (106 ml 1) from melanoma patients or normal donors were either left in CM without stimulation or stimulated in vitro in the following ways: (i) with irradiated (40 Gy) autologous tumour cells (auto-Me) at different responder to stimulator cell ratios ranging from 1:1 to 160:1 (MLTC); (ii) with an irradiated pool of lymphocytes from 4-6 different donors at 1:1 ratio; (iii) with IL-2-containing supernatants from allostimulated normal PBL or PHAstimulated, lectin free IL-2 (Associated Biomedics System, Buffalo, NY, USA) at 20-40% final concentration. The concentration of IL-2 was selected after preliminary kinetics experiments. Effector cells kept in 2 ml of CM, using 24 wells cluster plates (Costar, 3524, Cambridge, MA, USA), were harvested after 6-7 days of incubation at 37°C in a 5% CO2 and washed 3 times before testing in 5'Cr-release assay. 5I Cr-release assay Table I also shows that the reactivity of unstimulated Pt-PBL was evident only in 3/27 cases (11%) and that autologous PBL were never lysed by allostimulated Pt-PBL, confirming previous findings of our laboratory (Fossati et al., 1982) .
Lysis of tumour cells by allostimulated Pt-PBL is not due to cross-reactivity between allogeneic N-PBL and melanoma cells The above findings prompted us to investigate whether autologous tumour lysis by allostimulated Pt-PBL occurred through a cross-reactivity between normal alloantigens and TAA as has been found for some experimental neoplasms ( (Parmiani et al., 1979; Greenberg et al., 1981; Kedar et al., 1982a; Sensi et al., 1983) . To test this hypothesis, PBL from 13 metastatic melanoma patients were stimulated with allogeneic N-PBL from single donors and then tested for cytotoxicity on auto-Me and on the N-PBL used as stimulators. Inhibitor to target cell ratio Figure 1 Singly allostimulated Pt-PBL tested on autoe 3338 (a) and stimulating normal PBL (b). Inhibition with auto-Me (0) and stimulating PBL (0). E:T ratio 25:1. Specific cytotoxicity of unblocked allostimulated Pt-PBL was 48 and 39% on auto-Me and N-PBL respectively.
Generation of auto-Me cytotoxic cells by allostimulation or exposure to IL-2 To investigate whether generation of tumour cytotoxic Pt-PBL by allostimulation may occur through release of IL-2, PBL suspensions from each of 34 patients were divided into two aliquots which were then stimulated either by alloantigens or by exposure to IL-2-containing supernatants of MLC- Other experiments were done using K562 as target and both K562 and auto-Me as inhibitor cells. Figure 3 includes 2 of the 5 experiments which gave essentially similar results. As in Figure  2 , auto-Me strongly inhibited the cytotoxicity of allostimulated Pt-PBL on auto-Me targets, whereas K562 cells gave a significantly lower (borderline) inhibition at the same target to inhibitor cell ratio. When alloactivated effectors of the same patient were tested on K562, similar inhibition was obtained with K562 and with auto-Me, although in one case (N. 11652) auto-Me gave a slightly higher inhibition at 10-5: 1 inhibitor to target ratio, (0) Table IV , the unseparated lymphocytes lysed both targets after alloactivation; allostimulated T3-cells were also cytotoxic for auto-Me and K562 whereas the T3+ population was cytotoxic for auto-Me cells but did not kill K562 cells. In all the experiments both T3 + and T3 -cells incorporated [3H]-TdR after 6 days of stimulation by alloantigens.
These results indicate that both T3 + and T3-cells, present in the initial Pt-PBL, can be alloactivated to become cytotoxic against auto-Me cells. Moreover, allostimulated T3 + cells lysed auto-Me cells without showing NK-like activity on K562 targets. Thus, the lysis of metastatic auto-Me cells by alloactivated Pt-PBL represents the sum of the cytotoxic activity of both T3 + and T3-effectors.
Discussion
In the present paper we have confirmed on a larger number of cases the capacity of alloantigens (MLC) but not of auto-Me (MLTC), to activate Pt-PBL with a lytic activity on metastatic auto-Me cells. Lysis of fresh autologous tumours by Pt-PBL stimulated in MLC has been reported for melanomas and a variety of histologically different human neoplasms (Zarling et al., 1978b; Strausser et al., 1981; Fossati et al., 1982; Taylor & Bradley, 1983) .
To explain these findings it has been suggested by experiments on some animal and human tumours that the lysis of tumour cells by T lymphocytes occurs through a cross-reaction between TAA and normal histocompatibility antigens of allogenic lymphocytes (Parmiani et al., 1979; Zarling & Bach, 1978a; Paciucci et al., 1980; Greenberg et al., 1981; Kedar et al., 1982b; Taylor & Bradley, 1983 Hurrell & Zarling, 1983) . The analysis of auto-Me cytotoxicity with MLCor MLTC-derived clones also tends to rule out the possibility that the lysis of autologous tumour targets by alloactivated Pt-PBL is due to crossreactivity between TAA and allogeneic MHC determinants (Vose & White, 1983; De Vries & Spits, 1984) .
Alternatively, the lysis of autologous tumour cells by allostimulated lymphocytes could be due to nonspecific effectors activated and expanded during MLC and having the features of NK-like cells rather than those of antitumour specific T cells (Kedar et al., 1982a These results may be explained by assuming that alloactivated effectors contain predominantly anti-tumour specific cytotoxic cells and, with a lower frequency, non-specific NK-like effectors, whereas in the IL-2-activated effectors the NK-like killers are the main cell subpopulation. Thus, the lysis of auto-Me by allostimulated cells may represent a combined effect of both specific and non-specific killer cells (Muul & Gately, 1984) .
The study of the phenotype of effector cells activated by MLC or by IL-2 did not allow dissection of the complex phenomenon since the lymphocyte markers expressed after stimulation were similar, although a reproducibly higher frequency of OKMl+ cells was found in the IL-2-activated cells. The results of cold target competition experiments suggested that two types of killers were generated by allostimulation, and, therefore, we decided to physically isolate the precursor cells and to study their properties. Both T3+ and T3-FACS-separated subsets were found to be activated by alloantigens and to lyse auto-Me; T3 -but not T3+ cells were also able to kill K562 targets. The lysis of auto-Me cells by alloactivated precursors T3+ cells indicates that anti-melanoma cytotoxic T cells may be present with a low frequency but not easily detectable by using bulk culture of the unstimulated lymphocyte population of cancer patients. After alloactivation, these T cells are expanded and lyse auto-Me cells possibly through the recognition of TAA different from those present on K562, as suggested by the failure of T3+ cells to lyse K562 and also by cold target competition experiments. Recent findings from this and other laboratories (Vose & White, 1983; De Vries & Spits, 1984; Knuth et al., 1984; Anichini et al., 1985) on the successful isolation of cytotoxic T lymphocyte clones showing auto-Me restricted patterns of reactivity, support this interpretation. Thus, although clones of auto-Me killer lymphocytes may be present in the Pt-PBL population, in our experience the bulk population of Pt-PBL cannot be stimulated by metastatic auto-Me cells . Allostimulation then represents, at least for metastatic melanoma, a useful procedure for activating antitumour T cells present in the initial Pt-PBL with a frequency too low to be detected in a MLTC, and for overcoming the immunosuppressive activity of metastatic autoMe cells .
In addition to alloactivated T3+ cells, T3-PBL were also found to lyse auto-Me targets, a result in agreement with those reported by Vanky et al. (1984) , who found that T3-cells (or a low Percoll density population) with or without activation by Hu-IFN-a were responsible for the lysis of tumour cells. Furthermore, Grimm et al. (1982) have shown that T3-cells are the precursors of IL-2-activated (LAK) effectors. In our study the activation and proliferation of FACS-separated T3-cells by allostimulation may be due to IL-2 released from the irradiated pool of allogeneic lymphocytes.
The results of cold target inhibition experiments and those on precursor cells would indicate that allostimulation and IL-2 activation may work through different mechanisms. We do not have a clear explanation for that; it is possible that when exogeneous IL-2 is added to PBL, activation of non-specific NK-like population occurs which masks the minor antitumour specific killer precursor cells. During MLC, however, there may be a triggering of T helper cells which, when activated, release IL-2 continuously and gradually thus activating both antitumour specific and NK-like effectors.
